Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Tumor metabolism of malignant gliomas.

Ru P, Williams TM, Chakravarti A, Guo D.

Cancers (Basel). 2013 Nov 8;5(4):1469-84. doi: 10.3390/cancers5041469.

2.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
3.

[Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].

Favre G.

Bull Acad Natl Med. 2014 Feb;198(2):321-36; discussion 337-8. French.

PMID:
26263707
4.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA.

Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. Epub 2006 Oct 7. Review.

5.
6.

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.

Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart MJ.

Cancer Treat Rev. 2013 Dec;39(8):935-46. doi: 10.1016/j.ctrv.2013.03.009. Epub 2013 May 3.

PMID:
23643661
7.

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy.

Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O, Iida M, Ohgami N, Tamura H, Kawamoto Y, Kato M.

Dermatol Res Pract. 2012;2012:354191. doi: 10.1155/2012/354191. Epub 2011 Oct 12.

8.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA.

Oncotarget. 2011 Mar;2(3):135-64. Review.

9.

The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?

Lv J, Wang J, Chang S, Liu M, Pang X.

Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):17-26. doi: 10.1093/abbs/gmv102. Epub 2015 Oct 19. Review.

PMID:
26487443
10.

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.

Britten CD.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1395-409. doi: 10.1007/s00280-013-2121-1. Epub 2013 Feb 27. Review.

PMID:
23443307
11.

Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals.

von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR, Troppmair J.

Mol Cell Biol. 2001 Apr;21(7):2324-36.

12.

Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.

Makinoshima H, Takita M, Saruwatari K, Umemura S, Obata Y, Ishii G, Matsumoto S, Sugiyama E, Ochiai A, Abe R, Goto K, Esumi H, Tsuchihara K.

J Biol Chem. 2015 Jul 10;290(28):17495-504. doi: 10.1074/jbc.M115.660498. Epub 2015 May 28.

13.

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.

Asati V, Mahapatra DK, Bharti SK.

Eur J Med Chem. 2016 Feb 15;109:314-41. doi: 10.1016/j.ejmech.2016.01.012. Epub 2016 Jan 12. Review.

PMID:
26807863
14.

The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.

Dasgupta T, Haas-Kogan DA.

Front Oncol. 2013 May 10;3:110. doi: 10.3389/fonc.2013.00110. eCollection 2013.

15.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
16.

Lipid metabolism emerges as a promising target for malignant glioma therapy.

Guo D, Bell EH, Chakravarti A.

CNS Oncol. 2013 May;2(3):289-99. Review.

17.

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.

Yuen HF, Abramczyk O, Montgomery G, Chan KK, Huang YH, Sasazuki T, Shirasawa S, Gopesh S, Chan KW, Fennell D, Janne P, El-Tanani M, Murray JT.

Biosci Rep. 2012 Aug;32(4):413-22. doi: 10.1042/BSR20120050.

18.

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.

Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bögler O.

J Transl Med. 2016 Feb 9;14:46. doi: 10.1186/s12967-016-0803-2.

19.

Targeting SREBP-1-driven lipid metabolism to treat cancer.

Guo D, Bell EH, Mischel P, Chakravarti A.

Curr Pharm Des. 2014;20(15):2619-26. Review.

20.

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA.

Leukemia. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66. Epub 2011 Apr 15. Review.

PMID:
21494257

Supplemental Content

Support Center